1. Home
  2. OTLK vs AIRE Comparison

OTLK vs AIRE Comparison

Compare OTLK & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$2.06

Market Cap

42.8M

Sector

Health Care

ML Signal

HOLD

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$0.53

Market Cap

40.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTLK
AIRE
Founded
2010
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.8M
40.7M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
OTLK
AIRE
Price
$2.06
$0.53
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$5.25
$2.00
AVG Volume (30 Days)
5.5M
5.3M
Earning Date
12-26-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,505,322.00
$4,149,567.00
Revenue This Year
N/A
$411.48
Revenue Next Year
$342.80
$141.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
994.18
52 Week Low
$0.79
$0.14
52 Week High
$3.39
$4.49

Technical Indicators

Market Signals
Indicator
OTLK
AIRE
Relative Strength Index (RSI) 69.44 50.20
Support Level $1.51 $0.49
Resistance Level $2.10 $0.57
Average True Range (ATR) 0.20 0.05
MACD 0.02 0.01
Stochastic Oscillator 93.22 66.49

Price Performance

Historical Comparison
OTLK
AIRE

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.

Share on Social Networks: